PromarkerEso
REVOLUTIONISING ESOPHAGEAL CANCER DETECTION
PromarkerEso is a potential world-first blood test for both esophageal adenocarcinoma and patients with pre-malignant condition Barrett’s esophagus which affects 1-2% of adults and can arise from chronic acid reflux. The PromarkerEso test could provide an early screening tool to minimise the requirements for an endoscopy.
The prototype test has correctly identified 89% of patients with esophageal adenocarcinoma and 92% of patients without the disease.
The PromarkerEso Test
Esophageal cancer accounts for 1 in 20 cancer deaths worldwide, with the 5-year survival rate less than 20%. Diagnosis currently requires a specialist endoscopy procedure. There is a pressing need for innovation in earlier and simpler diagnosis.
Proteomics International’s simple blood test measures biomarkers – protein ‘fingerprints’ in the blood – to diagnose both esophageal adenocarcinoma and Barrett’s esophagus.
The prototype test shows strong diagnostic performance, detecting up to 90% of people with esophageal adenocarcinoma [ASX:08Sep2023]. The PromarkerEso biomarker panel has been clinically validated in a second independent patient group [ASX:01Feb2024].
PromarkerEso is a patent-protected targeted mass spectrometry (LC-MRM-MS) laboratory developed test.
To learn more about the PromarkerEso test, please email PromarkerEso@proteomics.com.au
To subscribe to the Company’s updates, please email ASX subscribe to subscribe@proteomics.com.au
PromarkerEso – Key Presentations and Publications
Validation of Biomarkers for Oesophageal Cancer |
Poster. S. Bringans, E. Schoeman, N. Dorta Scott, R. Wang, P. Galettis, R. Lipscombe. 29th Annual Lorne Proteomics Symposium, Lorne, Australia, 31 January – 3 February 2024. Link |
A novel serum glycoprotein biomarker panel for screening of esophageal adenocarcinoma and surveillance of Barrett’s esophagus |
Oral Presented by R. Lipscombe. R. Lipscombe, M.N. Duong, R. Casey, G. Fernadez, S. Bringans, K. Peters, M.M. Hill, P. Tan, L. Chen.19th ISDE World Congress for Esophageal Diseases in Toronto, September 2023. Link |
Development of a Lectin Bead-based Diagnostic Test for Oesophageal Cancer |
Oral Presented by S. Bringans. S. Bringans, M.N. Duong, K. Chen, G. Fernandez, T. Casey, P. Di Prinzio, M.M. Hill, R. Lipscombe. 28th Annual Lorne Proteomics Symposium, Lorne, Australia, February 2023. |
Semi-Automated Lectin Magnetic Bead Array (LeMBA) for Translational Serum Glycoprotein Biomarker Discovery and Validation |
Publication. M. Dutt, M.N. Duong, S. Bringans, R. Richards, R. Lipscombe, M.M. Hill. Book Chapter in Serum/Plasma Proteomics: Methods and Protocols. Springer US, New York, NY, 2023. Link |
Establishing a Mass Spectrometry Based Diagnostic Test for Oesophageal Cancer |
Oral Presented by R. Lipscombe. M.N. Duong, S. Bringans, S. Chen, G. Fernadez, T. Casey, C. Laming, P. Di Prinzio, M.M. Hill, R. Lipscombe. 18th ISDE World Congress for Esophageal Diseases in Tokyo, Japan, September 2022. Link |
Evaluation of Serum Glycoprotein Biomarker Candidates for Detection of Esophageal Adenocarcinoma and Surveillance of Barrett’s Esophagus |
Publication. A. K Shah, G. Hartel, I. Brown, C. Winterford, R. Na, K. Le Cao, B.A. Spicer, M.A. Dunstone, W.A. Phillips, R.V. Lord, A.P. Barbour, D.I. Watson, V. Joshi, D.C. Whiteman, M.M. Hill; Mol Cell Proteomics 2018; 17(12): 2324–2334. Link |
Esophageal Adenocarcinoma
Esophageal adenocarcinoma is the most common form of esophageal cancer and is an area of significant unmet medical need. The overall five-year survival rate for this cancer is less than 20%, and 1 in 20 cancer deaths worldwide in 2018 were attributed to esophageal cancer. An estimated 10-15% of patients with chronic acid reflux develop Barrett’s esophagus, a condition which is asymptomatic and affects 1-2% of Western populations[1].
Screening for esophageal adenocarcinoma currently requires a specialist endoscopy procedure that costs US $2,750 per patient in the United States[2], where the total expenditure on treating esophageal cancer was $2.9 billion in 2018[3]. People with Barrett’s esophagus are much more likely to get esophageal adenocarcinoma and are advised to get regular endoscopies to screen for esophageal cancer.
